B1 3. (Amended) A polypeptide comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 2, or to a metalloproteinase, disintegrin domain, prodomain, or thrombospondin submotif, thereof.

Replace claim 15 with the following claim:

B2 15. (Amended) A pharmaceutical composition for the treatment of arthritis, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity and rejection, cachexia, allergy, cancer, tissue ulcerations, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joints implants, atherosclerosis, aortic aneurysm, congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neurodegenerative diseases, autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, infertility or diabetic shock comprising a therapeutically effective amount of a polypeptide of claim 16 in combination with a pharmaceutically acceptable carrier.

Kindly add the following claims:

B3 16. The polypeptide of claim 3 comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 2, or to a metalloproteinase, disintegrin domain, prodomain, or thrombospondin submotif, thereof.

17. The polypeptide of claim 16 comprising an amino acid sequence having at least 95% identity to the amino acid sequence of the metalloproteinase domain.

18. The polypeptide of claim 3 comprising an amino acid sequence having at least 97% identity to the amino acid sequence of SEQ ID NO: 2, or to a metalloproteinase, disintegrin domain, prodomain, or thrombospondin submotif, thereof.

19. The polypeptide of claim 17 comprising an amino acid sequence having at least 97% identity to the amino acid sequence of the metalloproteinase domain.

20. The polypeptide of claim 18 comprising an amino acid sequence having at least 99% identity to the amino acid sequence of SEQ ID NO: 2, or to a metalloproteinase, disintegrin domain, prodomain, or thrombospondin submotif, thereof.

21. The polypeptide of claim 20 comprising an amino acid sequence having at least 99% identity to the amino acid sequence of the metalloproteinase domain.

22. The polypeptide of claim 4 comprising said metalloproteinase domain.

23. The polypeptide of claim 3 having 5 to 10 amino acids substituted, deleted, or added, or combinations of such changes.

24. The polypeptide of claim 17 having 5 to 10 amino acids substituted, deleted, or added, or combinations of such changes.

25. The polypeptide of claim 3 having 1 to 5 amino acids substituted, deleted, or added, or combinations of such changes.

26. The polypeptide of claim 17 having 1 to 5 amino acids substituted, deleted, or added, or combinations of such changes.

27. The polypeptide of claim 3 having 1 amino acid substituted, deleted, or added, or combinations of such changes.

28. The polypeptide of claim 17 having 1 amino acid substituted, deleted, or added, or combinations of such changes.

29. The polypeptide of claim 23 comprising 5 to 10 conservative amino acid substitutions.

30. The polypeptide of claim 24 comprising 5 to 10 conservative amino acid substitutions.

31. The polypeptide of claim 25 having 1 to 5 conservative amino acid substitutions.

cancel

32. The polypeptide of claim 26 comprising 1 to 5 conservative amino acid substitutions.